Clinical Outcomes Following Lens Exchange Of Opacified Intraocular Lenses In A Large Series Of Patients

To evaluate visual and refractive outcomes of eyes that required an exchange of IOL due to intraocular lens opacification.

Private Refractive Surgery (Optical Express)

The study included 1,208 eyes of 987 patients who underwent a lens exchange between July 2018 and June 2022. The opacified lenses comprised various Oculentis Mplus IOL models. The mean time to opacification, the incidence rate of opacification (the percentage of opacified lenses from the total number of implanted lenses), and the visual and refractive outcomes prior to and post lens exchange were assessed.

Mean time between primary Oculentis Mplus lens implant and the exchange of IOL was 6.7 ± 2.2 years. Incidence rate of opacification ranged between 0.3% and 4.2%, depending on the Oculentis Mplus model. Following explant of the opacified IOL, 37.8% and 62.2% received a monofocal and multifocal IOL respectively. At the last available visit after the lens exchange, 81.4% of eyes had a UCDVA of 20/20 or better, and 99.6% achieved a UCDVA of 20/40 or better. Of all eyes, 78.1% and 95.2% had the last available manifest spherical equivalent within ±0.50 and ± 1.00 D, respectively. Serious adverse events included 6 cases of posterior capsule rupture, and one retinal detachment from the 1,208 eyes.

Opacified IOLs can be exchanged with good visual and refractive outcomes. To replace the explanted lens, a different multifocal IOL was the lens of choice in the majority of cases. The incidence of serious adverse events was relatively low. Exchange surgery in the presence or absence of a previous YAG capsulotomy is safe and effective.